@#AIM: To appraise the therapeutic effect of dual laser(micro-pulse laser and traditional laser)and single intravitreal injection with conberceptin on macular edema secondary to ischemic branch retinal vein occlusion.<p>METHODS: A prospective cohort study was conducted. 83 patients(83 eyes)participated in the study from November 2017 to November 2018. They were randomly divided into two groups. Group A(42 eyes)accepted the treatment of dual laser and single intravitreal injection with conbercept and group B(41 eyes)accepted only traditional laser treatment and single intravitreal injection with anti-VEGF, and the aim is to analysis the data including BCVA, CMT in follow-up visit after treatment 1, 3, 6mo.<p>RESULTS: After 1mo: in group A, BCVA improved from 0.88±0.11 to 0.43±0.19(<i>P</i><0.01), CMT changed from 595.00±61.12 to 379.8±76.08μm(<i>P</i><0.01). In group B, BCVA changed from 0.82±0.19 to 0.39±0.16(<i>P</i><0.01)while CMT changed from 601.70±81.37 to 381.50±70.92 μm(<i>P</i><0.01). There were no difference between two groups(<i>P</i>>0.05). After 3mo: in group A, BCVA raised to 0.13±0.07(<i>P</i><0.01), CMT reduced to 282.80±31.93μm(<i>P</i><0.01); in group B, BCVA hold on 0.41±0.09(<i>P</i>=1.00), CMT retained 395.80±34.53μm(<i>P</i>=0.99). The improvement of BCVA and CMT were better in group A(<i>P</i><0.01). After 6mo: in group A, BCVA maintained 0.28±0.12(<i>P</i><0.01), CMT keeped 335.60±33.98μm(<i>P</i>=0.02); in group B, BCVA rebounded to 0.77±0.15(<i>P</i><0.01), CMT was 579.60±19.61μm(<i>P</i><0.01). Both BCVA and CMT were better in group A than group B(<i>P</i><0.01). No serious complications happened in all phases.<p>CONCLUSION: The treatment of dual laser and single intravitreal injection with conbercept for macular edema secondary to ischemic branch retinal vein occlusion can maintain good effect more than 3mo.